Propafenone for Conversion and Prophylaxis of Atrial Fibrillation

American Journal of Cardiology

Volumn 79, Issue 4, 1997, Pages 418-423

  Stroobandt, Roland ^a   Stiels, Brigitte ^b   Hoebrechts, Rafaël ^b  

^a Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; PROPAFENONE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROBABILITY; PROPAFENONE;

EID: 0031568667     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00779-5     Document Type: Article

References (13)

1. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
2. Leitch JW, Klein GJ, Yee R, Guiraudon GM. Sinus node-atrioventricular node isolation: long-term results with the "corridor" operation for atrial fibrillation. J Am Coll Cardiol 1991;17:970-975.
3. Grey E, Silverman DI. Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. PACE 1993;16:2235-2240.
4. UK Propafenone PVST Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2250-2257.
5. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-819.
6. Kannel WB, Abott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982;3606:1018-1022.
7. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991;84:40-48.
8. Antman EM. Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. J Cardiovasc Electrophysiol 1995;6:962-971.
9. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-338.
10. Suttorp MJ, Kingma HJ, Jessurun ER, Lie-A-Huen L, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-1727.
11. Falk RH, Knowlton AA, Gotlieb NE, Batinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 1987;106:503-506.
12. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time is gone? Ann Intern Med 1991;114:573-575.
13. Cohen IS, Herschel J, Cohen S. Adverse reactions to quinidine in hospitalized patients: findings based on data from Boston Colloborative Drug Surveillance Program. Prog Cardiovasc Dis 1977;20:151-163.